Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition

• Published in: Journal for immunotherapy of cancer Vol. 10; no. 1; p. e004008
• Main Authors: Ghosh, Nilasha, Postow, Michael, Zhu, Chengsong, Jannat-Khah, Deanna, Li, Quan-Zhen, Vitone, Greg, Chan, Karmela K, Bass, Anne R
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.01.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Aged; Anti-Citrullinated Protein Antibodies - blood; Antibodies; Antibodies, Antinuclear - blood; antibody formation; Antigens; Arthritis; Autoantibodies - blood; Autoimmune diseases; autoimmunity; Biomarkers; Cancer; Clinical trials; Clinical/Translational Cancer Immunotherapy; Connective tissue; Diabetes; Disease; Female; Humans; humoral; Immune Checkpoint Inhibitors - adverse effects; Immune system; immunity; Immunoglobulins; Immunoglobulins - blood; Immunotherapy; Inflammation; Inflammatory bowel disease; Lymphocytes; Male; Melanoma; Melanoma - drug therapy; Melanoma - immunology; Middle Aged; Patients; Plasma; Rheumatoid Factor - blood; Thyroid gland; melanoma; antibody formation; immunity; autoimmunity; humoral; immunotherapy
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2021-004008

IntroductionImmune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have been successful in treating advanced malignancies; however, they also cause immune-related adverse events (irAE). Given that some irAE are clinically similar to traditional autoimmune diseases, autoantibodies hav...